Hormonal
Obesity-induced chronic low-grade inflammation causes insulin resistance by activating proinflammatory cytokines (TNF-α, IL-6) and signaling pathways (JNK, NF-κB, JAK-STAT), which interfere with insulin signaling and action.
If you are overweight, your body fat is not just stored energy; it is biologically active tissue releasing inflammatory signals that block insulin. Managing weight and reducing visceral fat are critical steps to lowering this inflammation and improving insulin sensitivity.
Obesity-associated chronic low-grade inflammation is responsible for the decrease of insulin sensitivity... Obesity might increase the expression of some inflammatory cytokines and activate several signaling pathways, both of which are involved in the pathogenesis of insulin resistance by interfering with insulin signaling and action.
Why this rating
This is a review article synthesizing multiple experimental studies and animal models, providing strong mechanistic evidence, though direct human clinical trial data for specific interventions is limited.
Source
Mechanisms Linking Inflammation to Insulin Resistance
Li Chen et al. · International Journal of Endocrinology · 2015
DOI 10.1155/2015/508409
More from this paper
- Specific inflammatory cytokines (TNF-α, IL-6) and signaling pathways (JNK, NF-κB, JAK-STAT) directly impair insulin signaling by causing serine phosphorylation of IRS-1 and reducing GLUT4 expression.Good
- Hybrid training (voluntary and electrical muscle contractions) can ameliorate insulin resistance by suppressing serum IL-6 levels in skeletal muscle.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →